Search Results - "Pataky, Reka"

The impact of the early COVID-19 pandemic on healthcare system resource use and costs in two provinces in Canada: An interrupted time series analysis by Zeitouny, Seraphine, Cheung, Douglas C, Bremner, Karen E, Pataky, Reka E, Pequeno, Priscila, Matelski, John, Peacock, Stuart, Del Giudice, M. Elisabeth, Lapointe-Shaw, Lauren, Tomlinson, George, Mendlowitz, Andrew B, Mulder, Carol, Tsui, Teresa C. O, Perlis, Nathan, Walker, Jennifer D, Sander, Beate, Wong, William W. L, Krahn, Murray D, Kulkarni, Girish S

“…Introduction The aim of our study was to assess the initial impact of COVID-19 on total publicly-funded direct healthcare costs and health services use in two…”
Get full text

Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions by Pataky, Reka E., Bryan, Stirling, Sadatsafavi, Mohsen, Peacock, Stuart, Regier, Dean A.

“…Background and Objective Precision medicine highlights the importance of exploring heterogeneity in the effectiveness and costs of interventions. Our objective…”
Get full text

Strategies to accelerate the elimination of cervical cancer in British Columbia, Canada: a modelling study by Pataky, Reka E, Izadi-Najafabadi, Sara, Smith, Laurie W, Gottschlich, Anna, Ionescu, Diana, Proctor, Lily, Ogilvie, Gina S, Peacock, Stuart

“…To eliminate cervical cancer in Canada by 2040, defined as an annual age-standardized incidence rate (ASIR) lower than 4.0 per 100 000 women, the Canadian…”
Get full text

Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework by Pataky, Reka E., Peacock, Stuart, Bryan, Stirling, Sadatsafavi, Mohsen, Regier, Dean A.

“…Mutations in KRAS and NRAS are predictive of poor response to cetuximab and panitumumab, two anti-epidermal growth factor receptor (EGFR) monoclonal antibodies…”
Get full text

Does Increasing Home Care Nursing Reduce Emergency Department Visits at the End of Life? A Population-Based Cohort Study of Cancer Decedents by Seow, Hsien, PhD, Barbera, Lisa, MD, MPA, Pataky, Reka, MSc, Lawson, Beverley, MSc, O'Leary, Erin, MSc, Fassbender, Konrad, PhD, McGrail, Kim, PhD, Burge, Fred, MD, MSc, Brouwers, Melissa, PhD, Sutradhar, Rinku, PhD

“…Abstract Context Despite being commonplace in health care systems, little research has described home care nursing's effectiveness to reduce acute care use at…”
Get full text

Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada by Pataky, Reka E., Bryan, Stirling, Sadatsafavi, Mohsen, Peacock, Stuart, Regier, Dean A.

“…Background Cetuximab and panitumumab, two anti-EGFR therapies, are widely used for third-line therapy of metastatic colorectal cancer (mCRC) with wild-type…”
Get full text

Health Care Costs Attributable to Prostate Cancer in British Columbia, Canada: A Population-Based Cohort Study by Zhang, Wei, Guh, Daphne P, Mohammadi, Tima, Pataky, Reka E, Tam, Alexander C T, Lynd, Larry D, Conklin, Annalijn I

“…We aimed to estimate the total health care costs attributable to prostate cancer (PCa) during care phases by age, cancer stage, tumor grade, and primary…”
Get full text

Real-world cost-effectiveness of panel-based genomic testing to inform therapeutic decisions for metastatic colorectal cancer by Pataky, Reka E., Weymann, Deirdre, Bosdet, Ian, Yip, Stephen, Bryan, Stirling, Sadatsafavi, Mohsen, Peacock, Stuart, Regier, Dean A.

“…Mutations in KRAS and NRAS are associated with a lack of response to cetuximab and panitumumab, two biologics used for third-line therapy of metastatic…”
Get full text

Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group by Dai, Wei Fang, de Oliveira, Claire, Blommaert, Scott, Pataky, Reka E, Tran, David, Aurangzeb, Zeb, Kendell, Cynthia, Folkins, Chris, Somayaji, Chandy, Dowden, Jeff, Cheung, Winson, Strumpf, Erin, Beca, Jaclyn M, McClure, Carol, Urquhart, Robin, McDonald, James Ted, Alvi, Riaz, Turner, Donna, Peacock, Stuart, Denburg, Avram, Mercer, Rebecca E, Muñoz, Caroline, Parmar, Ambica, Tadrous, Mina, Takhar, Pam, Chan, Kelvin K W, On Behalf Of The CanREValue Collaboration

“…Canadian provinces routinely collect patient-level data for administrative purposes. These real-world data (RWD) can be used to generate real-world evidence…”
Get full text

Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada by Guan, Qi, Aktar, Suriya J, Pataky, Reka E, Stephen, Mariet Mathew, Marques, Maud, Gambaro, Karen, Rachedi, Kahina, Forster, Katharina, Strub, Samara, Stock, David, de Léséleuc, Louis, Cheung, Winson Y, Peacock, Stuart, Farrer, Christie, Gavura, Scott, Tadrous, Mina, Grant, Robert C, Chan, Kelvin K W

“…Niraparib was recently funded in Canada for the maintenance treatment of ovarian cancer following platinum-based chemotherapy. However, the drug's safety…”
Get full text

“Bring the Hoses to Where the Fire Is!”: Differential Impacts of Marginalization and Socioeconomic Status on COVID-19 Case Counts and Healthcare Costs by Cheung, Douglas C., Bremner, Karen E., Tsui, Teresa C.O., Croxford, Ruth, Lapointe-Shaw, Lauren, Giudice, Lisa Del, Mendlowitz, Andrew, Perlis, Nathan, Pataky, Reka E., Teckle, Paulos, Zeitouny, Seraphine, Wong, William W.L., Sander, Beate, Peacock, Stuart, Krahn, Murray D., Kulkarni, Girish S., Mulder, Carol

“…Local health leaders and the Director General of the World Health Organization alike have observed that COVID-19 “does not discriminate.” Nevertheless, the…”
Get full text

Economic evaluation of prostate cancer risk assessment methods: A cost‐effectiveness analysis using population data by Mohammadi, Tima, Guh, Daphne P., Tam, Alexander C. T., Pataky, Reka E., Black, Peter C., So, Alan, Lynd, Larry D., Zhang, Wei, Conklin, Annalijn I.

“…Background The current prostate cancer (PCa) screening standard of care (SOC) leads to unnecessary biopsies and overtreatment because decisions are guided by…”
Get full text

Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial by Kwon, Janice S, McTaggart-Cowan, Helen, Ferguson, Sarah E, Samouëlian, Vanessa, Lambaudie, Eric, Guyon, Frédéric, Tidy, John, Williamson, Karin, Gleeson, Noreen, de Kroon, Cor, van Driel, Willemien, Mahner, Sven, Hanker, Lars, Goffin, Frédéric, Berger, Regina, Eyjólfsdóttir, Brynhildur, Kim, Jae-Weon, Brotto, Lori A, Pataky, Reka, Yeung, Shirley S T, Chan, Kelvin K W, Cheung, Matthew C, Ubi, Juliana, Tu, Dongsheng, Shepherd, Lois E, Plante, Marie

“…SHAPE (Simple Hysterectomy And PElvic node assessment) was an international phase III trial demonstrating that simple hysterectomy was non-inferior to radical…”
Get full text

Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces by Pataky, Reka E., Beca, Jaclyn, Tran, David, Dai, Wei Fang, Dvorani, Erind, Isaranuwatchai, Wanrudee, Peacock, Stuart, Alvi, Riaz, Cheung, Winson Y., Earle, Craig C., Gavura, Scott, Chan, Kelvin K. W.

“…Background. Real-world evidence can be a valuable tool when clinical trial data are incomplete or uncertain. Bevacizumab was adopted as first-line therapy for…”
Get full text

Initial health care costs for COVID-19 in British Columbia and Ontario, Canada: an interprovincial population-based cohort study by Tsui, Teresa C.O., Zeitouny, Seraphine, Bremner, Karen E., Cheung, Douglas C., Mulder, Carol, Croxford, Ruth, Del Giudice, Lisa, Lapointe-Shaw, Lauren, Mendlowitz, Andrew, Wong, William W.L., Perlis, Nathan, Sander, Beate, Teckle, Paulos, Tomlinson, George, Walker, Jennifer D., Malikov, Kamil, McGrail, Kimberlyn M., Peacock, Stuart, Kulkarni, Girish S., Pataky, Reka E., Krahn, Murray D.

“…BACKGROUNDCOVID-19 imposed substantial health and economic burdens. Comprehensive population-based estimates of health care costs for COVID-19 are essential…”
Get full text

Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study by de Oliveira, Claire, PhD, Bremner, Karen E., BSc, Pataky, Reka, MSc, Gunraj, Nadia, MPH, Haq, Mahbubul, MSc, Chan, Kelvin, MD MSc, Cheung, Winson Y., MD MPH, Hoch, Jeffrey S., PhD, Peacock, Stuart, DPhil, Krahn, Murray D., MD MSc

“…Abstract Background Cancer incidence and treatment-related costs are rising in Canada. We estimated health care use and costs in the first year after diagnosis…”
Get full text

Strategies to accelerate the elimination of cervical cancer in British Columbia, Canada: a modelling study by Pataky, Reka E, Izadi-Najafabadi, Sara, Smith, Laurie W, Gottschlich, Anna, Ionescu, Diana, Proctor, Lily, Ogilvie, Gina S, Peacock, Stuart

“…Background: To eliminate cervical cancer in Canada by 2040, defined as an annual age-standardized incidence rate (ASIR) lower than 4.0 per 100000 women, the…”
Get full text

Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study by de Oliveira, Claire, MA PhD, Bremner, Karen E., BSc, Pataky, Reka, MSc, Gunraj, Nadia, MPH, Chan, Kelvin, MD MSc, Peacock, Stuart, MSc PhD, Krahn, Murray D., MD MSc

“…Background The first year after cancer diagnosis is a period of intensive treatment and high cost. We sought to estimate costs for the 21 most common cancers…”
Get full text

Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment by Regier, Dean A, Peacock, Stuart J, Pataky, Reka, van der Hoek, Kimberly, Jarvik, Gail P, Hoch, Jeffrey, Veenstra, David

“…An important challenge with the application of next-generation sequencing technology is the possibility of uncovering incidental genomic findings. A paucity of…”
Get full text

The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency by Cressman, Sonya, Peacock, Stuart J, Tammemägi, Martin C, Evans, William K, Leighl, Natasha B, Goffin, John R, Tremblay, Alain, Liu, Geoffrey, Manos, Daria, MacEachern, Paul, Bhatia, Rick, Puksa, Serge, Nicholas, Garth, McWilliams, Annette, Mayo, John R, Yee, John, English, John C, Pataky, Reka, McPherson, Emily, Atkar-Khattra, Sukhinder, Johnston, Michael R, Schmidt, Heidi, Shepherd, Frances A, Soghrati, Kam, Amjadi, Kayvan, Burrowes, Paul, Couture, Christian, Sekhon, Harmanjatinder S, Yasufuku, Kazuhiro, Goss, Glenwood, Ionescu, Diana N, Hwang, David M, Martel, Simon, Sin, Don D, Tan, Wan C, Urbanski, Stefan, Xu, Zhaolin, Tsao, Ming-Sound, Lam, Stephen

“…Lung cancer risk prediction models have the potential to make programs more affordable; however, the economic evidence is limited. Participants in the National…”
Get more information